• Citer

Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.

par Spigoni, Valentina;Fantuzzi, Federica ;Carubbi, Cecilia;Pozzi, Giulia;Masselli, Elena;Gobbi, Giuliana;Solini, Anna;Bonadonna, Riccardo R.C.;Dei Cas, Alessandra
Référence Cardiovascular diabetology, 19, 1, page (46)
Publication Publié, 2020-04-07

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

The clear evidence of cardiovascular benefits in cardiovascular outcome trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes might suggest an effect on atherosclerotic plaque vulnerability and/or thrombosis, in which myeloid angiogenic cells (MAC) and platelets (PLT) are implicated. We tested the effects of SGLT2i on inflammation and oxidant stress in a model of stearic acid (SA)-induced lipotoxicity in MAC and on PLT activation. The possible involvement of the Na+/H+ exchanger (NHE) was also explored.